Comparator: dorzolamide hydrochloride — Competitive Intelligence Brief

Comparator: dorzolamide hydrochloride (Comparator: dorzolamide hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic anhydrase inhibitor. Area: Ophthalmology.

phase 3 Carbonic anhydrase inhibitor Carbonic anhydrase II Ophthalmology Small molecule

Target snapshot

Comparator: dorzolamide hydrochloride (Comparator: dorzolamide hydrochloride) — Merck Sharp & Dohme LLC. Dorzolamide hydrochloride inhibits carbonic anhydrase II in the eye, reducing aqueous humor production and lowering intraocular pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: dorzolamide hydrochloride TARGET	Comparator: dorzolamide hydrochloride	Merck Sharp & Dohme LLC	phase 3	Carbonic anhydrase inhibitor	Carbonic anhydrase II
Azopt	BRINZOLAMIDE	Novartis	marketed	Carbonic Anhydrase Inhibitor [EPC]	carbonic anhydrase II	1998-01-01
Xalatan+Cosopt	Xalatan+Cosopt	University of Turin, Italy	marketed	Prostaglandin analog + carbonic anhydrase inhibitor + beta-blocker combination	Prostaglandin F receptor (FP receptor); carbonic anhydrase II; beta-adrenergic receptors
Latanoprost, Dorzolamide	Latanoprost, Dorzolamide	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	marketed	Prostaglandin analog + Carbonic anhydrase inhibitor combination	Prostaglandin F receptor (FP receptor) and Carbonic anhydrase II
timolol maleate and dorzolamide hydrochloride	timolol maleate and dorzolamide hydrochloride	University of Florida	marketed	Beta-adrenergic antagonist and carbonic anhydrase inhibitor combination	Beta-2 adrenergic receptor (timolol); carbonic anhydrase II (dorzolamide)
dorzolamide/timolol	dorzolamide/timolol	CT Glaucoma Associates	marketed	Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination	Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2)
Dorzolamide-timolol-brimonidine and latanoprost	Dorzolamide-timolol-brimonidine and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, alpha-2 agonist, and prostaglandin analog	Carbonic anhydrase II, beta-2 adrenergic receptor, alpha-2A adrenergic receptor, prostaglandin F receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic anhydrase inhibitor class)

1. Bausch & Lomb Incorporated · 2 drugs in this class
2. Actavis Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National University Hospital, Singapore · 1 drug in this class
6. Padagis LLC · 1 drug in this class
7. Rabin Medical Center · 1 drug in this class
8. Shahid Beheshti University of Medical Sciences · 1 drug in this class
9. Sun Pharmaceutical Industries Limited · 1 drug in this class
10. University Health Network, Toronto · 1 drug in this class